Routine HIV screening among blood donors in Buenos Aires (Argentina): Results from six years' experience and report of a single window-period donation

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 2, 2007, Pages 82-90

  Gendler, Silvina Alejandra ^a,b   Pascuccio, María Susana ^a  

^a HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^b NONE   (Argentina)

Author keywords

Blood donors; HIV antibodies; HIV core protein p24; Risk factors

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARGENTINA; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; RISK FACTOR; SCREENING; SERODIAGNOSIS; WESTERN BLOTTING;

EID: 33847673666     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13098568     Document Type: Article

References (37)

1. Centre for Disease Control: Update on acquired immunodeficiency syndrome (AIDS) among patients with haemophilia A. MMWR. 1982;31:644-51.
2. Leitman SF, Klein HG, Melpolder JJ, et al. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med. 1989;321:917-24.
3. Schreiber GB, Busch MP, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donors Study. N Engl J Med. 1996;334:1685-90.
4. Polywka S, Feldner J, Duttmann H, Laufs R. Diagnostic evaluation of a new combined HIV p24 antigen and anti-HIV-1/2/O screening assay. Clin Lab. 2001;47:351-6.
5. WHO Weekly Epidemiological Record: Revised recommendations for the selection and use of HIV antibody tests. 1997;72:81.
6. Centre for Disease Control: Revised Guidelines for HIV Counselling, Testing and Referral. MMWR. 2001;50(No. RR-19).
7. WHO Weekly Epidemiological Record: Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-II. 1990;65:281.
8. Centre for Disease Control: Interpretation and use of Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR. 1989;38 Suppl 7:1-7.
9. Food and Drug Administration, Department of Health and Human Services memorandum: Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen. 1995.
10. Gendler SA, Pascuccio MS, Carnevali L. Evaluación de la neutralización del antígeno p24 de HIV-1. Rev Arg Transf. 2001;XXVII Supl:32.
11. Gendler SA, Pascuccio MS, Carnevali L. Importancia de la determinación de HIV 1 Ag en el Banco de Sangre. A propósito de un caso. Rev Arg Transf. 2001;XXVII Supl:27.
12. Rey J, Tomeo A, Insua M, Santamarina D, Zárate N, Arrayago A, Ceriani S, et al. Prevalencia de anti-HIV, anti-HCV y HBsAg en dadores de sangre y pacientes prequirúrgicos en un Hospital de alta complejidad. Rev Arg Transf. 2003;XXIX Supl:28.
13. Ditzel DRC, Merolli R, Baldanzi GR, Almeida PTR. Teste para HIV, avaliar ensaios imuno enzimáticos (E.I.E.) e Western Blot (W.B.). Boletim da Sociedade Brasileira de Hematologia e Hemoterapia. 1998;XX Supl:72.
14. Otani MM, Salles NA, Barreto AM, Barreto CC, Chamone DF, Sabino EC. Evaluation of the concomitant use of two different EIA tests for HIV screening in Blood Banks. Rev Panam Salud Publica. 2003;13:172.
15. García MD, Talanda C, Pugliese P, Podzun I, Schmee E. Perfil serológico e inmunohematológico de donantes de sangre. Rev Arg Transf. 2003;XXIX Supl:19.
16. Pivetta M, Chialina S, Nicolorich V, Raillon M, Solís E. Estudio multicéntrico de seroprevalencia de enfermedades transmisibles por transfusión. Rev Arg Transf. 2003;XXIX Supl:30.
17. Pugliese MA, Payero MT, Ladino S, Rodríguez E, Fernández RJ. Evaluación de los marcadores serológicos en Banco de Sangre. Rev Arg Transf. 2001; XVII Supl:35.
18. Wendel S, Fachini RM, Oliveira LC, Levi JE, Lima LP, Hamada GS, et al. Blood Donor screening with p24 Antigen in Brazilian Blood Banks. Boletim da Sociedade Brasileira de Hematologia e Hemoterapia. 1998;XX Supl:20.
19. García CA, Agassis ACR, Marques Pereira JP, Soares IP, Farinon J, Balsan AM, et al. Anticorpo anti HIV I/II e Sua Associação com Outros Marcadores Sorológicos em Doadores de Sangue do Hospital de Clínicas de Porto Alegre: Actualização. Boletim da Sociedade Brasileira de Hematologia e Hemoterapia. 1998;XX Supl:71.
20. Blejer JL, Natalutti GR, García MM, Saguier MC, Salamone HJ. Infecciones por retrovirus en donantes de sangre. Rev Arg Transf. 2001;XXVII Supl:25.
21. Blejer JL, Chiera AO, Saguier MC, Salamone HJ. HIV P24 Antigen Screening in Two Blood Banks in Argentina. Transfusion. 2004;44 Supl:93A.
22. Le Corfec E, Le Pont F, Tuckwell HC, Rouzioux C, Costagliola D. Direct HIV testing in blood donations: Variation of the yield with detection threshold and pool size. Transfusion. 1999;39:1141.
23. Centre for Disease Control: Guidelines for Laboratory Testing and Result Reporting of Antibody to Hepatitis C Virus. MMWR. 2003;52(No. RR-3).
24. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion. 1995;35:91.
25. Roca MR, Navas MB, Pignata S. ¿Es conveniente el p24 en donantes? Rev Arg Transf. 2001;XXVII Supl:22.
26. Fontana D, Chiera A, Garcia C, Pombo F, Lampuri J, Borrajo G, et al. Tamizaje del Ag p24 del HIV-1 en donantes de sangre. Rev Arg Transf. 2001;XXVII Supl:31.
27. Scott E. The Blood Center as an Alternative Test Site for HIV Antibody Testing. Transfusion. 1997;37 Supl:85.
28. Muzzio E, Trione N, Soto I, Corti M. Prevalencia de infeccio¿n por virus de hepatitis C (HCV) en una unidad de internacio¿n de pacientes con SIDA. Actas del 6.° Congreso Argentino de SIDA 2003; p. 58.
29. Kremer L, Trevin̄o E, Domínguez C, Marouch E, Barbás G, Leiva F, et al. Prevalencia de marcadores serológicos de agentes infecciosos en una población de individuos infectados con HIV en Córdoba, Argentina. Actas del 6.° Congreso Argentino de SIDA 2003; pag. 75.
30. Land K, Davenport P, Nizzi F, Sutor L, Sayers M. An Evaluation of HTLV I/II Confirmed Positive Donors. Transfusion. 2004;44 Supl:92A.
31. FDA, Department of Health and Human Services: Application of Nucleic Acid Testing to Blood Borne Pathogens and Emerging Technologies. OBRR/CBER/FDA Workshop 12/04/2001.
32. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L. Dynamics of HIV Viremia and Antibody Seroconversion in Plasma Donors: Implications for Diagnosis and Staging of Primary HIV Infection. AIDS. 2003;17:1871.
33. Aprili G, Gandini G, Piccoli P, Franchini M. Detection of an early HIV-1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period. Transfusion. 2003;43:848.
34. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975.
35. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, et al. Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid-Amplification Testing. N Engl J Med. 2004;351:760.
36. Kutner JM, Takatu PM, Polite MB, Takatu E, Rosenblit J, Szterling L, et al. NAT Detection in a Blood Donor at HIV Antigen and Antibody Window Period, First Case Reported in Brazil. Transfusion. 2004;44 Supl:93A.
37. Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, et al. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion. 2002;42:862.